Shots:
- The EU approved Tezspire as an add-on treatment with intranasal corticosteroids for adults with severe CRSwNP unresponsive to standard therapies; regulatory review is ongoing in China, Japan, and several other countries
- Approval was based on the P-III (WAYPOINT) study assessing Tezspire (SC) vs PBO to treat adults with severe CRSwNP for 52wks., followed by a post-treatment follow-up duration of 12-24wks. and safety profile and tolerability, presented at the 2025 AAAAI/WAO and simultaneously published in The NEJM
- Tezepelumab is a mAb that blocks TSLP, a key cytokine driving multiple inflammatory pathways linked to severe asthma, CRSwNP, and other inflammatory diseases
Ref: AstraZeneca | Image: AstraZeneca and Amgen | Press Release
Related News:- AstraZeneca and Amgen Report the CHMP’s Positive Opinion of Tezspire (Tezepelumab) for CRSwNP
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
